跳轉至內容
Merck
全部照片(1)

重要文件

查看所有文件

P2950000

扑米酮

European Pharmacopoeia (EP) Reference Standard

同義詞:

2-脱氧苯巴比妥, 5-乙基-5-苯基六氢嘧啶-4,6-二酮

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C12H14N2O2
CAS號碼:
125-33-7
分子量：:
218.25
MDL號碼:
MFCD00038662
分類程式碼代碼:
41116107
PubChem物質ID:
329820157
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

primidone

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

InChI 密鑰

DQMZLTXERSFNPB-UHFFFAOYSA-N

基因資訊

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

尋找類似的產品？ 前往 產品比較指南

相關類別

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Primidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Warning

危險聲明

H302,H351,H361d

危險分類

Acute Tox. 4 Oral - Carc. 2 - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

抱歉，我們目前沒有在線上提供本產品的COA

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sofia Markoula et al.
Therapeutic drug monitoring, 36(4), 494-498 (2014-02-25)
Lacosamide (LCM), a new antiepileptic drug (AED) approved as adjunctive therapy for the treatment of patients with partial-onset seizures, has limited pharmacokinetic and drug interaction data. The main objectives of the present study were to investigate the effects of dose
A Borromei et al.
Minerva medica, 78(22), 1687-1705 (1987-11-30)
A report is presented on 58 patients (46 males, 12 females) all suffering from post-traumatic epilepsy (PTE) and followed up for a minimum of 1 year to maximum of 23 years after the injury (mean 6.3 years). The type and
D F Lehmann
Medical toxicology and adverse drug experience, 2(5), 383-387 (1987-09-01)
Seven cases of crystalluria following primidone overdose have been reported since the 1950s. An eighth case of primidone crystalluria following overdose is presented. Because of low aqueous solubility (600 mg/L at 37 degrees C) which is directly proportional to temperature
Reo Tanoshima et al.
Therapeutic drug monitoring, 35(2), 145-149 (2013-03-19)
A 7.5-year-old girl who was treated with phenobarbital (PHB) for epilepsy was admitted with decreased levels of consciousness. She had been known to have high PHB levels of unknown cause, without symptoms. Her PHB levels were very high, as expected
D Christidis et al.
Seizure, 15(1), 64-66 (2005-11-29)
Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major cause of death accounting for 7-17% of the mortality among epileptic patients. Prolongation of QT-interval has been issued as a major mechanism in SUDEP since it is associated with fatal cardiac
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務